Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?

Dyne Therapeutics Ownership Summary

Dyne Therapeutics is owned by 12.46% institutional investors, 0.44% insiders, and 87.11% retail investors. Blackrock is the largest institutional shareholder, holding 9.11% of DYN shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.74% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Dyne Therapeutics	12.46%	0.44%	87.11%
Sector	Healthcare Stocks	232.51%	10.72%	-143.23%
Industry	Biotech Stocks	384.56%	10.58%	-295.14%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	7.39M	9.11%	$260.69M
Atlas venture life science advisors	9.13M	8.02%	$115.50M
Vanguard group	11.22M	7.91%	$219.38M
Blackrock funding, inc. /de	11.19M	7.89%	$218.89M
Janus henderson group	7.38M	7.31%	$173.81M
Fcpm iii services b.v.	5.46M	4.80%	$69.11M
Fmr	5.40M	4.74%	$68.33M
State street	5.27M	4.63%	$66.65M
Siren	4.73M	4.15%	$59.82M
Tcg crossover management	4.62M	4.05%	$58.38M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mpm asset management	682.38K	19.40%	$8.63M
Atlas venture life science advisors	9.13M	15.35%	$115.50M
Fcpm iii services b.v.	5.46M	13.81%	$69.11M
Saturn v capital management	2.67M	7.42%	$33.83M
University of wisconsin foundation	517.75K	5.55%	$6.55M
Bioimpact capital	1.45M	3.00%	$18.30M
Palo alto investors lp	1.26M	2.96%	$15.97M
Tcg crossover management	4.62M	2.87%	$58.38M
Logos global management lp	2.40M	2.72%	$30.36M
Vivo capital	2.61M	2.66%	$33.08M

Top Buyers

Holder	Shares	% Assets	Change
Marshall wace, llp	3.01M	0.04%	2.57M
Vestal point capital, lp	2.77M	1.59%	2.05M
Deep track capital, lp	2.00M	0.71%	2.00M
Blackrock	7.39M	0.01%	2.00M
State street	5.27M	0.00%	1.91M

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-9.71M
Holocene advisors, lp	-	-	-2.35M
Jefferies financial group	-	-	-1.80M
Perceptive advisors	540.44K	0.20%	-1.71M
Jennison associates	-	-	-1.21M

New Positions

Holder	Shares	% Assets	Change	Value
Paradigm biocapital advisors lp	1.90M	0.68%	1.90M	$24.02M
Polar capital	529.39K	0.03%	529.39K	$6.70M
University of wisconsin foundation	517.75K	5.55%	517.75K	$6.55M
Federated hermes	464.80K	0.02%	464.80K	$9.09M
Clearbridge investments	407.79K	0.01%	407.79K	$7.98M

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-9.00
J.safra asset management	-11.00
Cva family office	-12.00
Federation des caisses desjardins du quebec	-20.00
Amundi	-21.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	48	-77.78%	17,667,612	-88.66%	12	0.07%	33	-77.40%	8	-80.49%
Sep 30, 2025	56	-72.00%	16,926,024	-86.84%	14	0.12%	39	-66.95%	9	-82.69%
Jun 30, 2025	198	-5.71%	128,546,973	5.45%	112	0.92%	116	-10.08%	52	15.56%
Mar 31, 2025	25	-87.86%	30,059,507	-73.06%	27	0.22%	15	-85.98%	6	-90.32%
Dec 31, 2024	204	-1.45%	111,580,268	-0.38%	110	0.90%	105	-10.26%	62	14.81%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	3.90M	2.74%	827.02K
Vanguard US Total Market Shares ETF	2.65M	2.35%	2.40K
Fidelity Growth Compy Commingled Pl O	1.79M	1.78%	348.61K
Janus Henderson Glb Life Scn I2 USD	2.40M	1.69%	844.64K
iShares Russell 2000 ETF	2.27M	1.60%	-
JPMorgan Small Cap Growth A	1.94M	1.37%	496.51K
Janus Henderson Global Life Sciences D	1.89M	1.33%	80.26K
Janus Henderson Global Life Sciences	1.89M	1.33%	124.72K
Fidelity Growth Compy Commingled Pl S	1.84M	1.29%	2.39K
Fidelity Select Biotechnology	1.61M	1.13%	82.40K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 05, 2025	Cox John	CEO & President	Sell	$55.16K
Dec 05, 2025	Kerr Douglas	Chief Medical Officer	Sell	$18.23K
Dec 05, 2025	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$2.98K
Sep 05, 2025	Cox John	CEO & President	Sell	$35.40K
Sep 05, 2025	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$1.93K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	3
2025 Q3	1	5
2025 Q2	-	3
2025 Q1	-	9
2024 Q4	-	24

DYN Ownership FAQ

Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 12.46%, followed by 0.44% insiders and 87.10% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 384.56%, which Dyne Therapeutics falls below.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are Blackrock (7.39M shares, 9.11%), Atlas venture life science advisors (9.13M shares, 8.02%), and Vanguard group (11.22M shares, 7.91%). Together, they hold 25.04% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.40% of its assets in 682.38K Dyne Therapeutics shares, valued at 8.63M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Dyne Therapeutics shares, with 2.74% of its total shares outstanding invested in 3.9M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools